Skip to main content

Pharming Group N.V. announces that the first patient has been enrolled in its Phase III clinical trial in Japan evaluating leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Read the full press release below.

Hirokazu Kanegane, Professor of the Department of Child Health and Development, Tokyo Medical and Dental University, commented:

“The initiation of this clinical study is a positive step for the APDS community in Japan. With patients currently reliant on supportive treatments, the prospect of a disease-modifying treatment for this rare primary immunodeficiency could represent an exciting new treatment option for patients, their families, caregivers and their doctors in Japan.”

Cookies: This website uses cookies Check the cookies page for more information Accept Decline